Kinocilin inhibitors belong to a class of chemical compounds designed to selectively target and interfere with the activity of kinocilin, a less well-characterized protein or molecule in comparison to extensively studied counterparts in molecular biology.These inhibitors are developed with the aim of modulating the function of kinocilin, which may potentially be involved in various biological processes, though the specifics of its functions and interactions are still under investigation.
The primary mechanism of action for kinocilin inhibitors typically involves their interaction with the kinocilin protein or its associated molecules, leading to the disruption of its normal function. By inhibiting kinocilin, these compounds have the potential to impact cellular processes that are influenced by this molecule, although researchers are still working to unravel the precise roles and functions of kinocilin in cellular biology. Scientists studying kinocilin inhibitors aim to elucidate the specific roles and functions of kinocilin, contributing to our understanding of its potential significance within cellular processes. These inhibitors serve as valuable tools for advancing our knowledge of less-characterized proteins or molecules, enabling the exploration of new areas of molecular and cellular biology research. In this context, they contribute to expanding our understanding of the intricate world of cellular functions and molecular interactions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
A compound that inhibits bacterial RNA polymerase, potentially reducing gene transcription in prokaryotes. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
A compound that can intercalate into DNA and RNA, altering their function and potentially affecting gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
An agent that binds to DNA, inhibiting RNA polymerase II and reducing gene transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Interacts with DNA and inhibits RNA polymerase action across multiple species, leading to decreased mRNA synthesis. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Specifically inhibits eukaryotic RNA polymerase II, affecting mRNA synthesis and downstream protein expression. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
A quinoxaline compound that binds to DNA, inhibiting the binding of transcription factors and thus gene transcription. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
A synthetic anthracenedione that intercalates into DNA and inhibits topoisomerase II, affecting DNA replication and transcription. | ||||||
SN 38 | 86639-52-3 | sc-203697 sc-203697A sc-203697B | 10 mg 50 mg 500 mg | $119.00 $342.00 $883.00 | 19 | |
The active metabolite of the cancer drug irinotecan, inhibits topoisomerase I, leading to decreased DNA replication and transcription. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that can prevent the activation of MAP kinase pathway, potentially reducing the transcription of certain genes. | ||||||